Incretins Update: A Holistic Approach to Patients With Type 2 Diabetes and Cardiometabolic Comorbidities

Medical Minute 2: Multisystemic Actions of GIP/GLP-1 Coagonists
Download All
In this series of concise Medical Minute videos and ClinicalThought™ commentaries, expert faculty review the actions and clinical applications of current and emerging incretin-based therapies for persons with type 2 diabetes.
Carol Hatch Wysham, MD

Endogenous Incretins

In this concise Medical Minute video, become familiar with incretins and review how currently available GLP-1 receptor agonists target multiple pathophysiologic defects in T2D.

Carol Hatch Wysham, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Dietitians/Dietetic Technicians, Registered: maximum of 0.25 CPEU(s) Released: August 9, 2021 Expired: August 8, 2022

Learn about endogenous incretins, their downstream effects, and role in type 2 diabetes.

Carol Hatch Wysham, MD Released: August 9, 2021

A brief history of the discovery of incretins and how incretin-based therapies revolutionized modern diabetes care.

Carol Hatch Wysham, MD Released: August 13, 2021
Provided by Clinical Care Options
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Endocrine Society Logo
Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings